Director/PDMR Shareholding

Haleon PLC

22 May 2026

 

​Haleon plc: Director/PDMR Shareholding 

​22 May 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

On 21 May 2026, the Company was notified of the following transactions as detailed below.

1	Details of the issuer, emission allowance market participant
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the person discharging managerial responsibilities / person closely associated ("PCA")
a)	PDMR/PCA	PDMR
b)	Name	Dawn Allen
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument Identification code	Share GB00BMX86B70
b)	Nature of the transaction	Acquisition of Ordinary Shares as a result of dividend reinvestment
c)	Currency, Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.4022	2,596.07411
d)	Aggregated information	N/A
	- Aggregated volume
	- Price
e)	Date of the transaction	19 May 2026
f)	Place of the transaction	London Stock Exchange (XLON)

1

Details of the issuer, emission allowance market participant

a)

Name

Haleon plc

b)

LEI

549300PSB3WWEODCUP19

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the person discharging managerial responsibilities / person closely associated ("PCA")

a)

PDMR/PCA

PDMR

b)

Name

Brian McNamara

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of Instrument   Identification code

Share GB00BMX86B70

b)

Nature of the transaction

Acquisition of Ordinary Shares as a result of dividend reinvestment

c)

Currency, Price(s) and volume(s)

Price(s)

Volume(s)

£3.4022

24,891.04716

d)

Aggregated information

N/A

- Aggregated volume

- Price

e)

Date of the transaction

19 May 2026

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of Instrument Identification code

Share US4055521003

b)

Nature of the transaction

Acquisition of ADSs as a result of dividend reinvestment

c)

Currency, Price(s) and volume(s)

Price(s)

Volume(s)

$9.2446

4,414.93735

d)

Aggregated information

N/A

- Aggregated volume

- Price

e)

Date of the transaction

19 May 2026

f)

Place of the transaction

New York Stock Exchange (XNYS)

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com. 

 

END